TAMPA, Fla.--(BUSINESS WIRE)--May 8, 2006--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI - News) and its development partner have received approval from the United States Food and Drug Administration (FDA) for three additional combination pain product ANDAs (Abbreviated New Drug Applications), broadening the Company's pain product portfolio to better serve physicians in managing their patients, especially those with chronic pain. TEAMM Pharmaceuticals, Inc., Accentia's wholly owned specialty pharmaceutical subsidiary, holds the exclusive U.S. license for the marketing and sale of these three new formulations.
